Journal article
Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine
Vaccine, Vol.26(32), pp.4057-4061
2008
DOI: 10.1016/j.vaccine.2008.05.024
PMCID: PMC2605420
PMID: 18602726
Abstract
To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18–64) were randomized to receive either a single dose of TIV from multi-dose vials with thimerosal, TIV from pre-filled syringes without thimerosal, or placebo. Of the TIV recipients, 97.8% achieved a post-vaccination titer ≥40 against H1N1, 99.9% against H3N2 component, and 94.2% against influenza B. Few local or systemic adverse events were noted after vaccination with either TIV presentation. TIV was well tolerated and immunogenic.
Details
- Title: Subtitle
- Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine
- Creators
- H. Keipp Talbot - Vanderbilt University School of Medicine and Pediatrics, Vanderbilt University Medical Center, CCC 5311 MCN, 1161 21st Avenue South, Nashville, TN 37232, United StatesWendy Keitel - Baylor College of Medicine, 1 Baylor Plaza, Mail Stop BCM280, Houston, TX 77030, United StatesThomas R Cate - Baylor College of Medicine, 1 Baylor Plaza, Mail Stop BCM280, Houston, TX 77030, United StatesJohn Treanor - University of Rochester, 601 Elmwood Avenue, Box 689, Rochester, NY 14642, United StatesJames Campbell - University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, United StatesRebecca C Brady - Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 6014, Cincinnati, OH 45229-3039, United StatesIrene Graham - Saint Louis University, Health Sciences Center, FDT 8-N, 3635 Vista Avenue, St. Louis, MO 63110-0250, United StatesCornelia L Dekker - Stanford University School of Medicine, 300 Pasteur Drive, Room G312, Stanford, CA 94305, United StatesDora Ho - Stanford University School of Medicine, 300 Pasteur Drive, Room G312, Stanford, CA 94305, United StatesPatricia Winokur - University of Iowa and Iowa City VAMC, 200 Hawkins Drive, Iowa City, IA, United StatesEmmanuel Walter - Duke University, 4020 North Roxboro Road, Durham, NC, United StatesJillian Bennet - CSL Limited, 45 Poplar Road, Parkville, VIC 3052, AustraliaNeil Formica - CSL Limited, 45 Poplar Road, Parkville, VIC 3052, AustraliaGunter Hartel - CSL Limited, 45 Poplar Road, Parkville, VIC 3052, AustraliaMaryanne Skeljo - CSL Limited, 45 Poplar Road, Parkville, VIC 3052, AustraliaKathryn M Edwards - Vanderbilt University School of Medicine and Pediatrics, Vanderbilt University Medical Center, CCC 5311 MCN, 1161 21st Avenue South, Nashville, TN 37232, United States
- Resource Type
- Journal article
- Publication Details
- Vaccine, Vol.26(32), pp.4057-4061
- DOI
- 10.1016/j.vaccine.2008.05.024
- PMID
- 18602726
- PMCID
- PMC2605420
- NLM abbreviation
- Vaccine
- ISSN
- 0264-410X
- eISSN
- 1873-2518
- Publisher
- Elsevier Ltd
- Language
- English
- Date published
- 2008
- Academic Unit
- Infectious Diseases; Medicine Administration; Internal Medicine
- Record Identifier
- 9984094482602771
Metrics
18 Record Views